Skip to content
Brand AI

Kenvue

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2023

    Phenylephrine disclosure securities litigation

    A securities class action filed in the United States District Court for the District of New Jersey alleged that Kenvue’s registration statement contained misleading statements or omissions concerning internal controls, financial reporting, and risks or potential litigation connected with phenylephrine products and questions about their efficacy. The supplied material describes allegations and investor losses, not a final adjudication.

    Source